SCHEMBL2960714

SCHEMBL2960714

N#Cc1sc2c(ccc(=O)n2-c2cccnc2)c1Br

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.37
KAT2B Q92831 1/20 0.37
MAT2A P31153 8/20 0.37
ALOX12 P18054 1/20 0.35
ALDH1A1 P00352 4/20 0.34
MAPT P10636 4/20 0.34
GAA P10253 2/20 0.34
RECQL P46063 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
HTT P42858 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
PRMT5 O14744 1/20 0.33
MAPK14 Q16539 2/20 0.32
MDM2 Q00987 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2949358 0.86 EP300 (0.37) EP300KAT2BMAT2AALOX12ALDH1A1
SCHEMBL2781979 0.85 ADORA1 (0.37) ALDH1A1MAPTGAAMEN1POLB
SCHEMBL2956492 0.80 CDK4 (0.38) EP300KAT2BMAT2AALOX12ALDH1A1
SCHEMBL2955623 0.78 KDM4E (0.36) ALDH1A1MAPTMEN1KMT2A
SCHEMBL2960352 0.75 KMT2A (0.39) ALDH1A1MAPTHTTL3MBTL1MEN1
SCHEMBL2960302 0.74 KMT2A (0.37) ALDH1A1MAPTGAAHSD17B10L3MBTL1
SCHEMBL2954022 0.73 ALDH1A1 (0.37) ALDH1A1MAPTGAAHSD17B10HTT
SCHEMBL2781810 0.73 MEN1 (0.44) ALDH1A1MAPTHSD17B10MEN1POLB
SCHEMBL2958718 0.72 PREP (0.33)
SCHEMBL2780092 0.69 ALDH1A1 (0.38) ALDH1A1MAPTHSD17B10HTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK EP300 1168/4885KAT2B 1448/4885MAT2A 2474/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 EP300 1562/4885KAT2B 1309/4885MAT2A 3129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.